牛牛AI助理已提取核心訊息
RedHill Biopharma Ltd., a company listed on the United States Securities and Exchange Commission (SEC), has achieved a significant milestone with the Notice of Effectiveness issued by the SEC. The notice, which became effective on February 15, 2024, at 4:30 P.M., pertains to the Form F-1 filed by the company. This form is typically used by foreign issuers to register securities for offering in the U.S. market. The effectiveness of this form indicates that RedHill Biopharma has met the necessary regulatory requirements to proceed with its securities offering.
RedHill Biopharma Ltd., a company listed on the United States Securities and Exchange Commission (SEC), has achieved a significant milestone with the Notice of Effectiveness issued by the SEC. The notice, which became effective on February 15, 2024, at 4:30 P.M., pertains to the Form F-1 filed by the company. This form is typically used by foreign issuers to register securities for offering in the U.S. market. The effectiveness of this form indicates that RedHill Biopharma has met the necessary regulatory requirements to proceed with its securities offering.
在美國證券交易委員會（SEC）上市的公司RedHill Biopharma Ltd. 通過美國證券交易委員會（SEC）發佈的生效通知取得了重要的里程碑。該通知於2024年2月15日下午4點30分生效，涉及該公司提交的F-1表格。外國發行人通常使用此表格來註冊在美國市場發行的證券。該表格的有效性表明，RedHill Biopharma已滿足必要的監管要求，可以繼續進行證券發行。
在美國證券交易委員會（SEC）上市的公司RedHill Biopharma Ltd. 通過美國證券交易委員會（SEC）發佈的生效通知取得了重要的里程碑。該通知於2024年2月15日下午4點30分生效，涉及該公司提交的F-1表格。外國發行人通常使用此表格來註冊在美國市場發行的證券。該表格的有效性表明，RedHill Biopharma已滿足必要的監管要求，可以繼續進行證券發行。
有用
沒用